<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27473135</article-id><article-id pub-id-type="pmc">5035155</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2015674812</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000002970</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>120</subject><subject>130</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of hormone therapy on brain structure</article-title><subtitle>A randomized controlled trial</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kantarci</surname><given-names>Kejal</given-names></name><degrees>MD, MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Data safety monitoring board member for Takeda Global Research &#x00026; Development Center, Inc., Pfizer Inc. and Janssen Alzheimer Immunotherapy</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>R01 AG040042 (PI); 2011-2016, P50AG044170/P2(PI); 2012- 2017;</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Minnesota Partnership for Biotechnology and Medical Genomics; 2013-2015</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Tosakulwong</surname><given-names>Nirubol</given-names></name><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Lesnick</surname><given-names>Timothy G.</given-names></name><degrees>MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Zuk</surname><given-names>Samantha M.</given-names></name><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Gunter</surname><given-names>Jeffrey L.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH AG11378 support 2001-present</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Gleason</surname><given-names>Carey E.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Wharton</surname><given-names>Whitney</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Dowling</surname><given-names>N. Maritza</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Vemuri</surname><given-names>Prashanthi</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Senjem</surname><given-names>Matthew L.</given-names></name><degrees>MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>(1) Medtronic, Inc., 2013 - 2016 (2) Inovio Biomedical Corp., 2013 - 2016 (3) Parexel International Corporation, 2013 - 2016 (4) Oncothyreon, Inc., 2013 - 2015 (5) Gilead Sciences, Inc., 2014 - 2016</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Shuster</surname><given-names>Lynne T.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Bailey</surname><given-names>Kent R.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1) Novartis on the CANTOS study 2) Novartis on the PIONEER-HF study</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>AHRQ: R01HS 23077-1 statistical consultant NIA: P50AG 44170-4 Statistical collaborator NHLBI: R01HL36634-28 Statistical collaborator NIGMS: U01GM 74492-10 Statistical COllaborator NHLBI: R01HL 71478-10 Statistical COllaborator</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Rocca</surname><given-names>Walter A.</given-names></name><degrees>MD, MPH</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>2008 - to present: Revista de Neurologia (in Spanish) 2008 - to present: Maturitas 2009 - to present: Menopause Dr. Rocca is a member of the editorial boards of the above-listed journals. No compensation is received from any of these journals for his participation.</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Dr. Rocca receives research support from the NIH (R01 AG034676 [PI]; U01 AG006786 [co-investigator]; P50 AG044170[co-investigator]; and P01 AG04875 [co- investigator]).</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Jack</surname><given-names>Clifford R.</given-names><suffix>Jr</suffix></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>scientific advisory panels: Eli Lily</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>National Institutes of Health: R01 AG011378, U01 AG024904, RO1 AG041851, R01 AG037551, R01 AG043392, U01 AG006786</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>The Alexander Family Professorship for Alzheimer's disease Research, Mayo Clinic</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>own stock in Johnson and Johnson Stock/Stock Options, Medical Equipment &#x00026; Materials: Johnson and Johnson</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>Johnson and Johnson</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Asthana</surname><given-names>Sanjay</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Chair of DSMB for an NIH-funded study at Indiana University</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>1) Review Editor - Frontiers of Neuroscience; 2009 - Present 2) Associate Editor - Text book, entitled Hazzard's Geriatrics and Gerontology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Associate Editor - Text book, entitled Hazzard's Geriatric medicine and Gerontology</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Received research grant support as a site PI from the following companies to conduct clinical trials in patients with Alzheimer's disease (1) Wyeth Pharmaceutical, (2) Elan Pharmaceutical, (3) Eli Lilly, (4) Pfizer Pharmaceutical, 5) Merck, 6) Lundbeck</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) NIH/NIA 1P50 AG033514-01, PI, 5/01/09-3/31/2014; (2) NIH/NIA 1RO1 AG029624-01, PI, 4/15/07-3/31/2012; (3) NIH/NIA 5KO7 AG021582, PI, 4/15/06-1/31/2011; (4) NIH/NIA 2T32 AG00213-17, PI, 7/1/1991-4/30/2012; (5) NIH/NIA 1RO1 AG027161, Co-I, 4/15/07-3/31/2012; (6) NIH/NIA UO1 AG- 10483 Alzheimer?s Disease Cooperative Study, UW Site PI, 10/1/09-6/30/2012; (7) NIH/NIA UO1 Alzheimer?s Disease Cooperative Study, UW Site PI, 7/1/08-6/30/2011; (8) NIH/NIA UO1 127-01-ADNI-024, UW Site Co-I, 6/1/05- Ongoing; (9) NIH/NIA, NACC Subcontract 5 UO1 AG016976, PI, 7/1/2010-3/31/2014; (10) Department of Veterans Affairs (VA), Office of Academic Affiliations, PI, 12/1/06-open; (11) Department of Veterans Affairs (VA), Cooperative Study Program (CSP), Site PI and Member of the Study Executive Committee, 7/1/07-open; (12) State of Wisconsin, PI, 7/1/05-Recurring; (13) ADCS/NIA studies as a site PI</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>John A. Hartford Foundation Role: (PI) Period of Funding: 1/1/08-Present</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Virginia M.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>1985 - present Ad Hoc Reviewer: Circulation, Life Sciences, Microvascular Research, Physiology and Behavior, Chest, The American Journal of Cardiology, Journal of Vascular Surgery 1987 ? present Member, Editorial Board, American Journal of Physiology: Heart and Circulatory Physiology 1991 - present Member, Editorial Board, Journal of Cardiovascular Pharmacology 2008 ? present Member, Editorial Advisory Board, Journal of Pharmacology and Experimental Therapeutics 2010 ? present Member, Editorial Board, Biology of Sex Differences 2011 ? 2014 Member, Editorial Board, The Journal of Clinical Endocrinology &#x00026; Metabolism 2011 ? 2014 Member, Editorial Board, Journal of Cellular and Molecular Medicine 2011 ? 2014 Member, Editorial Board, Gender Medicine, The Journal for the Study of Sex and Gender Differences 2012- present Member, Editorial Board, Physiology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>National Institutes of Health HD 65987, Research Director, 2010-2015, National Institutes of Health AG 44170, Director and Principal Investigator, 2011-2016</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Kronos Longevity Research Institute</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Departments of Radiology (K.K., S.M.Z., J.L.G., P.V., M.L.S., C.R.J.), Health Sciences Research (N.T., T.G.L., K.R.B., W.A.R.), Internal Medicine (L.T.S.), Neurology (W.A.R.), and Surgery and Physiology and Biomedical Engineering (V.M.M.), Mayo Clinic, Rochester, MN; Department of Medicine (C.E.G., S.A.), School of Medicine and Public Health, University of Wisconsin and Geriatric Research, Education and Clinical Center, William S. Middleton Memorial, Veterans' Hospital, Madison, WI; Department of Neurology (W.W.), Emory University, Atlanta, GA; and Department of Biostatistics and Medical Informatics (N.M.D.), University of Wisconsin, Madison.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Kantarci: <email>kantarci.kejal@mayo.edu</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002970">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the authors.</p></fn></author-notes><pub-date pub-type="ppub"><day>30</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>8</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>87</volume><issue>9</issue><fpage>887</fpage><lpage>896</lpage><history><date date-type="received"><day>17</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 American Academy of Neurology</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2015674812.pdf"/><abstract><sec><title>Objective:</title><p>To investigate the effects of hormone therapy on brain structure in a randomized, double-blinded, placebo-controlled trial in recently postmenopausal women.</p></sec><sec><title>Methods:</title><p>Participants (aged 42&#x02013;56 years, within 5&#x02013;36 months past menopause) in the Kronos Early Estrogen Prevention Study were randomized to (1) 0.45 mg/d oral conjugated equine estrogens (CEE), (2) 50 &#x003bc;g/d transdermal 17&#x003b2;-estradiol, or (3) placebo pills and patch for 48 months. Oral progesterone (200 mg/d) was given to active treatment groups for 12 days each month. MRI and cognitive testing were performed in a subset of participants at baseline, and at 18, 36, and 48 months of randomization (n = 95). Changes in whole brain, ventricular, and white matter hyperintensity volumes, and in global cognitive function, were measured.</p></sec><sec><title>Results:</title><p>Higher rates of ventricular expansion were observed in both the CEE and the 17&#x003b2;-estradiol groups compared to placebo; however, the difference was significant only in the CEE group (<italic>p</italic> = 0.01). Rates of ventricular expansion correlated with rates of decrease in brain volume (<italic>r</italic> = &#x02212;0.58; <italic>p</italic> &#x02264; 0.001) and with rates of increase in white matter hyperintensity volume (<italic>r</italic> = 0.27; <italic>p</italic> = 0.01) after adjusting for age. The changes were not different between the CEE and 17&#x003b2;-estradiol groups for any of the MRI measures. The change in global cognitive function was not different across the groups.</p></sec><sec><title>Conclusions:</title><p>Ventricular volumes increased to a greater extent in recently menopausal women who received CEE compared to placebo but without changes in cognitive performance. Because the sample size was small and the follow-up limited to 4 years, the findings should be interpreted with caution and need confirmation.</p></sec><sec><title>Classification of evidence:</title><p>This study provides Class I evidence that brain ventricular volume increased to a greater extent in recently menopausal women who received oral CEE compared to placebo.</p></sec></abstract><funding-group><award-group><funding-source>NIH</funding-source><award-id>NS66147, AG029624, and AG44170</award-id></award-group><award-group><funding-source>NIH</funding-source><award-id>R01AG040042, principal investigator [PI], R21 NS066147 [PI], Mayo Clinic Alzheimer's Disease Research Center/project 1 P50 AG16574/P1 [PI], P50 AG44170/project 2 [PI], and R01 AG11378 [coinvestigator]</award-id></award-group><award-group><funding-source>NIH</funding-source><award-id>R01-AG011378, RO1-AG037551, U01-HL096917, U01-AG032438, U01-AG024904</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>cme</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>ppage</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Hormone therapy with conjugated equine estrogens (CEE) and medroxyprogesterone acetate initiated later in menopause increased the risk of dementia in the Women's Health Initiative Memory Study (WHIMS).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Whether alternative formulations of hormone therapy can preserve neuronal integrity and decrease the risk of dementia when administered early in menopause remains controversial.<sup><xref rid="R2" ref-type="bibr">2</xref><xref ref-type="bibr" rid="R3">&#x02013;</xref><xref rid="R10" ref-type="bibr">10</xref></sup> Determining the effects of hormone therapy during the early postmenopausal years on the risk of dementia would require decades of follow-up. However, noninvasive imaging markers related to cognitive health have been suggested as short-term surrogate outcomes to assess the effects of menopausal hormone therapy on the brain. Thus, age-associated changes in brain structure on MRI can be used to measure the effects of estrogens on the brains of postmenopausal women.</p><p>The Kronos Early Estrogen Prevention Study (KEEPS) tested the hypothesis that menopausal hormone therapy administered early after the onset of menopause would slow progression of atherosclerosis.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> However, hormone therapy in KEEPS did not affect progression of atherosclerosis<sup><xref rid="R12" ref-type="bibr">12</xref></sup> or cognitive function<sup><xref rid="R13" ref-type="bibr">13</xref></sup> within the 4 years of hormone therapy. We report here the results of an ancillary study to KEEPS, conducted to determine the effects of oral CEE and transdermal 17&#x003b2;-estradiol therapy on changes in structural brain MRI over 4 years. The ventricular volume change was chosen as the primary outcome measure because it was the most reliable measure of the change in brain structure associated with aging and cognitive function.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> The secondary outcome measures included changes in whole brain and white matter hyperintensity (WMH) volumes.</p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s1-1"><title>Participants.</title><p>KEEPS was a multicenter, randomized, double-blinded, placebo-controlled clinical trial in recently menopausal women (n = 727). Participants enrolled in KEEPS were between 42 and 59 years of age, within 5 to 36 months past their last menses, and were in good cardiovascular health.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> An ancillary MRI study to KEEPS was conducted from February 2006 through August 2011 at the Mayo Clinic to investigate the effects of hormone treatment on brain structure. Exclusion criteria for enrollment in the ancillary KEEPS-MRI study were MRI contraindications for safety and neurologic disorders.</p><p>Baseline MRI examinations and cognitive testing were completed following randomization but with concealed allocation and before treatment initiation. The treatments were as follows: (1) oral CEE (0.45 mg/d; Premarin, Pfizer, New York, NY); (2) transdermal 17&#x003b2;-estradiol (17&#x003b2;-estradiol skin patch, 50 &#x003bc;g/d; Climara, Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ); or (3) placebo pills and patch. Estrogens were administered through 2 different routes, oral or transdermal, because of the increased risk of venous thrombosis with oral estrogens. It was hypothesized that transdermal 17&#x003b2;-estradiol would have a different effect on risk factors for atherosclerosis and thromboembolic disease compared to oral CEE. Progesterone was given orally (micronized progesterone, 200 mg/d; Prometrium, AbbVie Inc., North Chicago, IL) for 12 days at the beginning of each month to both active treatment groups to protect the endometrium. Follow-up MRI examinations and cognitive testing were performed at 18 months (estrogen-only phase), 36 months (progesterone phase; to determine whether there would be an effect on the trajectory of change in outcome measures due to progesterone), and at 48 months (estrogen-only phase).<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p></sec><sec id="s1-2"><title>Standard protocol approvals, registrations, and patient consents.</title><p>The present study (NCT00154180; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00154180/">https://clinicaltrials.gov/ct2/show/NCT00154180</ext-link>) was approved by the Mayo Clinic institutional review board (no. 224104). All participants provided written informed consent.</p></sec><sec id="s1-3"><title>Cognitive testing.</title><p>A confirmatory factor analysis was used to assess the underlying structure of baseline cognitive data from the KEEPS cognitive and affective study, and to derive summary scores (n = 662).<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Using standard criteria for model fit, the cognitive variables were summarized in 4 specific independent domains and a general domain representing global cognitive function.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p></sec><sec id="s1-4"><title>Magnetic resonance imaging.</title><p>MRI studies were performed on a single 1.5-tesla system, with an 8-channel phased-array coil (GE Healthcare, Waukesha, WI). A 3-dimensional, magnetization-prepared rapid-acquisition gradient echo sequence was acquired for volumetric analysis, and fluid-attenuated inversion recovery (FLAIR) MRI was acquired for quantification of WMH volume. Changes in ventricle and whole brain volumes were calculated automatically from each registered magnetization-prepared rapid-acquisition gradient echo scan pair using the boundary shift integral and expressed in cubic centimeters of volume change from baseline for each follow-up time point as previously described.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> The boundary shift integral is designed to monitor brain structural changes and treatment effects in clinical trials of Alzheimer disease.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p><p>WMH volumes were derived from semiautomated segmentation of FLAIR images as previously described.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Briefly, WMH on FLAIR images were segmented using an automated slice-based seed initialization and region growing method. A trained image analyst (S.Z.), blinded to treatment group as well as to the sequence of the follow-up scans, inspected the segmented WMH mask overlaid on the FLAIR image. Every segmented image was visually compared to the unprocessed FLAIR image and false-positive WMH labels resulting from artifacts were edited to be excluded from the WMH mask. The WMH masks on follow-up scans were also visually compared to the baseline WMH mask for consistent editing of the artifacts. One of the baseline FLAIR scans failed quality control and was therefore excluded from the analysis. Longitudinal change in WMH was expressed in cubic centimeters of volume change from baseline for each follow-up MRI.</p></sec><sec id="s1-5"><title>Statistical analysis.</title><p>Baseline characteristics were compared among groups using analysis of variance followed by Tukey pairwise tests, 2-sample <italic>t</italic> tests, or Fisher exact tests, as appropriate. Changes in the outcomes from baseline were shown using plots of mean values and their associated 95% confidence intervals at each time point. Associations between the outcome variables at 48 months were shown using scatterplots with Pearson correlation coefficients adjusted for age. In a secondary analysis, the percent change in the whole brain, ventricular, and WMH volumes over 18, 36, and 48 months in CEE and 17&#x003b2;-estradiol groups was compared to placebo by <italic>t</italic> tests.</p><p>Ventricular and whole brain volumes, WMH, and global cognitive score changes over time were modeled using linear mixed models as planned a priori, with each model containing time from baseline, treatment group, and time from baseline &#x000d7; treatment group interactions as fixed-effects predictors. These models incorporated random effects for subject-specific intercepts and slopes. Coefficient estimates with their associated 95% confidence intervals, and categories of significance were reported for these models. Treatments were compared to each other and to placebo. Treatment by time interactions were of primary interest because any treatment effect would likely manifest as a change in the trajectories over time rather than a sudden jump in the magnitude of the outcomes. Because the primary analyses on the effects of each of the 2 hormone therapies on brain structure were determined a priori, there was no adjustment for multiple comparisons in reporting these results. Furthermore, results from the 2 hormone therapy groups were not pooled because of the differences in formulations and route of administration.</p><p>For our primary analysis of ventricular volumes using linear mixed models, with &#x003b1; = 0.05 and the smallest group size of 29 for conservative estimates, there was 80% power to detect a difference in slopes over time between groups of 0.296 cm<sup>3</sup> per year. For example, for a woman starting at the mean baseline ventricular volume of 19.6 cm<sup>3</sup>, a 1.5% increase could be detected per year because of treatment (a 2.3% increase in the volume after 18 months, 4.5% after 36 months, and 6.0% after 48 months).</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><p>All women enrolled in KEEPS at Mayo Clinic Rochester (n = 118) were invited to participate in the ancillary MRI study. Five participants were excluded because of neurologic disorders or MRI contraindications; 12 women declined participation. Eligible women underwent a baseline MRI (n = 101) before starting treatment. MRI data were analyzed for the 95 participants who repeated at least one MRI examination at 18 (n = 92), 36 (n = 87), or 48 (n = 79) months (<xref ref-type="fig" rid="F1">figure 1</xref>). Baseline global cognitive performance and whole brain volumes were not different among treatment and placebo groups. However, ventricular volumes were larger in the 17&#x003b2;-estradiol treatment group (<italic>p</italic> = 0.025) and WMH volumes were larger in the CEE treatment group (<italic>p</italic> = 0.008) compared to placebo at baseline after adjusting for total intracranial volume (<xref ref-type="table" rid="T1">table 1</xref>). None of the participants had silent infarcts on baseline and follow-up MRI examinations.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>KEEPS-MRI study participation</title><p>Participation and exclusions from the KEEPS-MRI study are shown. Participants who had a baseline MRI before onset of treatment and had at least one follow-up MRI at months 18, 36, or 48 were included in the analysis. *There were 5 exclusions at baseline MRI: MRI incompatible implant (CEE group); posterior fossa developmental abnormality and hydrocephalus (17&#x003b2;-estradiol group); 2 participants with multiple sclerosis and one participant with a benign brain tumor (placebo group). There was an exclusion of a participant from the 17&#x003b2;-estradiol group who developed breast cancer after completing the 18-month scan and underwent chemotherapy. Her structural MRI data at months 36 and 48 were excluded from analysis because of the potential adverse effects of chemotherapy on brain structure. One of the baseline fluid-attenuated inversion recovery scans failed quality control and therefore had to be excluded from the analysis. CEE = conjugated equine estrogens; KEEPS = Kronos Early Estrogen Prevention Study.</p></caption><graphic xlink:href="NEUROLOGY2015674812FF1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the participants</p></caption><graphic xlink:href="NEUROLOGY2015674812TT1"/></table-wrap><p>Whole brain volumes decreased in the CEE (<italic>p</italic> = 0.004) and the 17&#x003b2;-estradiol (<italic>p</italic> = 0.002) treatment groups, but not in the placebo group (<italic>p</italic> = 0.09) over 48 months. However, the decline in whole brain volume was not significantly different between the placebo and treatment groups (CEE and 17&#x003b2;-estradiol). Ventricular volumes increased in both the treatment (CEE and 17&#x003b2;-estradiol) and the placebo groups over 48 months (<italic>p</italic> &#x0003c; 0.001). Increases in ventricular volumes were greater only in the CEE treatment group compared to the placebo group (<italic>p</italic> = 0.01). WMH volume increased in the CEE (<italic>p</italic> = 0.004) and 17&#x003b2;-estradiol (<italic>p</italic> = 0.002) groups, but not in the placebo group (<italic>p</italic> = 0.42) over 48 months. However, the increase in WMH volumes was not different when comparing the CEE (<italic>p</italic> = 0.10) and 17&#x003b2;-estradiol (<italic>p</italic> = 0.06) groups to the placebo group (<xref ref-type="fig" rid="F2">figure 2</xref>). The results of mixed-effects models are summarized in <xref ref-type="table" rid="T2">table 2</xref>. Changes in any of the MRI measures did not differ between the CEE and 17&#x003b2;-estradiol groups (table e-1 at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002970">Neurology.org</ext-link>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Changes in the MRI raw value measurements and global cognitive function in treatment groups</title><p>Mean change (cm<sup>3</sup>) and 95% confidence intervals at 18, 36, and 48 months for whole brain volume (A), ventricular volume (B), and WMH volume (C). Mean change in global cognition <italic>z</italic> scores and 95% confidence intervals at 18, 36, and 48 months (D) is displayed. Increases in ventricular volumes were greater in the CEE treatment group than in the placebo group (<italic>p</italic> = 0.01), but not in the 17&#x003b2;-estradiol group compared to the placebo group (<italic>p</italic> = 0.09). CEE = conjugated equine estrogens; WMH = white matter hyperintensity.</p></caption><graphic xlink:href="NEUROLOGY2015674812FF2"/></fig><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Annual change in imaging markers on mixed-effects model</p></caption><graphic xlink:href="NEUROLOGY2015674812TT2"/></table-wrap><p>Because baseline WMH volumes were higher in the CEE group than in the placebo group, we tested whether baseline WMH modified the treatment &#x000d7; time interactions by adding baseline WMH and baseline WMH &#x000d7; time to the mixed models. The parameter estimates and <italic>p</italic> values for treatment &#x000d7; time were then compared with and without the baseline adjustment to see if they differed. The primary interest was in possible effects of baseline WMH on the significant CEE vs placebo difference in ventricular volume change. After adjusting for baseline WMH, increases in ventricular volumes in the CEE treatment group remained greater than in the placebo group (<italic>p</italic> = 0.011), but did not reach statistical significance in the 17&#x003b2;-estradiol group compared with the placebo group (<italic>p</italic> = 0.06) (table e-2).</p><p>Percent increases in ventricular volume from baseline to 18, 36, and 48 months were greater in the CEE group but not in the 17&#x003b2;-estradiol group compared to placebo at all time points. On the contrary, percent increases in WMH volume from baseline were greater in the CEE group only at 48 months and in the 17&#x003b2;-estradiol group only at 18 months compared to placebo (<xref ref-type="table" rid="T3">table 3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Percentage of change in imaging markers</p></caption><graphic xlink:href="NEUROLOGY2015674812TT3"/></table-wrap><p>Global cognitive function did not change in the treatment or the placebo group, and there were no differences in global cognitive change between CEE, 17&#x003b2;-estradiol, and placebo groups over 48 months (<xref ref-type="fig" rid="F2">figure 2</xref>).</p><p>Over the 48 months of follow-up, the increase in ventricular volume correlated with the decline in whole brain volume (<italic>r</italic> = &#x02212;0.58; <italic>p</italic> &#x02264; 0.001) and with the increase in WMH volume (<italic>r</italic> = 0.27; <italic>p</italic> = 0.01) after adjusting for age.</p><p>In the CEE group, increases in ventricular volume at 18 months correlated with timing of initiation of treatment in relation to the onset of menopause, after adjusting for age. Women who initiated hormone therapy later in menopause had greater increases in ventricular volume at 18 months (<italic>r</italic> = 0.40; <italic>p</italic> = 0.03). This association was weaker at 36 months (<italic>r</italic> = 0.35; <italic>p</italic> = 0.07) and at 48 months (<italic>r</italic> = 0.26; <italic>p</italic> = 0.24). By contrast, there were no correlations between increases in ventricular volume and timing of initiation of 17&#x003b2;-estradiol treatment, after adjusting for age.</p></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>The major finding of this study is that the rates of increase in ventricular volumes were greater in recently menopausal women who received oral CEE therapy compared to placebo over 4 years without significant differences in changes in global cognition. Although the rates of changes in MRI measures did not differ between the CEE and 17&#x003b2;-estradiol groups, the rates of increase in ventricular volume did not reach statistical significance in the 17&#x003b2;-estradiol group, compared to placebo, probably because of our limited sample size and short follow-up. Furthermore, increases in ventricular volume over 18 months of treatment were greater in the CEE group if hormone therapy was initiated later in menopause.</p><p>It is difficult to compare the findings of the present study with the findings of other studies in the literature, because the earlier studies were conducted in older women, and the structural MRI assessments were cross-sectional and not longitudinal, and were performed many years after initiation of hormone therapy. However, given these limitations, greater rates of structural brain changes with CEE therapy compared to placebo in the present study are consistent with the finding of lower regional brain volumes in women who initiate hormone therapy at age 65 years or older in the WHIMS-MRI, when the structural MRI changes were observed after the study medications were stopped.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Our findings also agree with observational studies that found larger ventricular volumes in women using hormone therapies<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> but contradict other studies that showed larger brain volumes in women who used postmenopausal hormone therapy compared to women who did not.<sup><xref rid="R23" ref-type="bibr">23</xref><xref ref-type="bibr" rid="R24">&#x02013;</xref><xref rid="R26" ref-type="bibr">26</xref></sup></p><p>Although measurements of both whole brain and ventricular volumes are surrogates for the change in global brain structure and correlate with each other, differences between CEE treatment and placebo groups were statistically significant when comparing the rates of ventricular volume change but not the rates of whole brain volume change. This may be attributable to the differences in noise and measurement variability. Indeed, smaller sample sizes are needed to detect treatment effects using ventricular volume change compared to whole brain volume change.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><p>Brain volumes quantified on MRI decrease and ventricular volumes increase during physiologic aging.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> The decrease in brain volume accelerates in cognitively normal older adults several years before they develop mild cognitive impairment<sup><xref rid="R14" ref-type="bibr">14</xref></sup> or dementia.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Although structural MRI changes are adequate surrogate markers for tracking the progression of preclinical neurodegenerative brain pathology many years before the onset of cognitive decline, they may not be ideal markers for detecting the effects of specific treatments that might modify brain function or pathology.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Evidence of hormonal effects on brain structure in younger women is limited to studies in premenopausal women. Premenstrual decreases in estrogen and progesterone levels are associated with increased ventricular volumes,<sup><xref rid="R30" ref-type="bibr">30</xref></sup> and postmenstrual increases in estrogen levels are associated with preservation of ventricular structure and even increases in hippocampal volume.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Furthermore, larger gray matter volumes were found in oral contraceptive users compared to nonusers.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Both cyclic increases in endogenous hormones and exogenous administration of hormones appear to preserve ventricular volumes and increase brain volumes in premenopausal women, in contrast to the findings of the present study with exogenous administration of hormones in postmenopausal women. Therefore, transient retention of sodium and water, which has been implicated in the premenstrual increases in ventricular volume when endogenous estrogen is low, would not explain the finding of increased ventricular volume in postmenopausal women who received estrogens.</p><p>WMH volume gradually increased only in the CEE and 17&#x003b2;-estradiol treatment groups but not the placebo group. These increases in WMH volumes over 48 months correlated with the increases in ventricular volumes, suggesting that similar mechanisms may be driving both of these structural changes. Accelerated volumetric changes in brain structure and WMH are associated with cognitive decline in older adults, including ischemic small vessel disease and Alzheimer disease.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> A relationship between longitudinal increases in WMH and ventricular volumes has been reported in a cohort with atherosclerosis, slightly older than the participants of the KEEPS-MRI study (mean age 53 vs 57 years) and with a high percentage of men, suggesting that cerebral small vessel disease may underlie the parallel increases in WMH and ventricular volumes.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> Although the pathologic underpinnings of WMH and ventricular volume increases in women with good cardiovascular health is unclear, there is evidence that the WMH increases in participants of the KEEPS-MRI study were associated with thrombogenic microvesicles in the blood at baseline.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Thrombogenic microvesicles are related to the progression of atherosclerosis.<sup><xref rid="R35" ref-type="bibr">35</xref></sup></p><p>In the CEE group, ventricular volumes increased less in women who initiated hormone therapy earlier than later in menopause, albeit only during the first 18 months. This association gradually weakened at 36 and 48 months of treatment. Since the mean time to starting CEE was 20 months past menopause (range: 5&#x02013;36), the window in which hormone therapy causes less ventricular expansion appears to be limited to approximately 3 years into menopause. This time window may be associated with a gradual loss of estrogen receptor &#x003b1; in the postmenopausal brain.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p><p>Women participating in the KEEPS-MRI study were in good cardiovascular and neurologic health, and well educated, which may limit generalization of findings to a broader population. However, in this homogeneous population of relatively healthy women, hormone therapy effects on brain structure were independent of concurrent cardiovascular or neurologic diseases. Furthermore, the sample size and the MRI changes in brain volumes were small, limiting statistical power. Therefore, the changes observed in the 17&#x003b2;-estradiol group compared to placebo may reach statistical significance with a longer duration of the study. Further investigation including larger numbers of participants and longer follow-up is warranted. Even though the treatment and placebo groups did not differ at baseline regarding cardiovascular risk factors, the CEE group had greater WMH volume than the placebo group. Some of the differences observed across groups at baseline are not surprising given the relatively small number of women included in the MRI ancillary study. Randomization does not guarantee a balanced allocation across treatment groups when the numbers are small. We found no evidence that greater WMH volume at baseline influenced the findings on ventricular volume change. We acknowledge, however, that post hoc statistical comparisons are subject to biases.</p><p>Among older women who received estrogen treatment in the WHIMS-MRI, lower regional brain volume was associated with greater cognitive decline or dementia.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> By contrast, we observed a change in brain structure over 4 years of hormone therapies that did not correlate with changes in cognitive function of recently menopausal women. The interpretation of this absence of an association between imaging findings and cognitive findings remains uncertain. On one hand, it is possible that the women who experienced structural brain changes with hormone therapies early in menopause will develop cognitive decline during an extended follow-up, and if proven, the imaging findings would be useful early surrogates of future clinical events. On the other hand, it is possible that these brain changes will subside after cessation of hormone therapy, and women who had structural brain changes during the 4 years of postmenopausal hormone therapy will not have an increased risk of cognitive decline over a longer follow-up.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> In the WHIMS-MRI studies, even though the brain volumes were smaller in women who received CEE therapies compared to placebo years after the end of the treatment phase, the rates of decline in brain volumes remained similar to the placebo group in the years following the cessation of CEE therapies.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> Thus, the short-term effects of estrogen treatment on the vascular system and on the brain may be different from long-term effects, and even opposed. Participants of the KEEPS-MRI study are being followed to determine whether these changes in brain structure are persistent after 4 years of hormone treatment and whether women with structural brain changes will develop clinically detectable cognitive decline.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Supplement</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_87_9_887__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_WNL.0000000000002970_Table_e-1.pdf"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_WNL.0000000000002970_Table_e-2.pdf"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title>Accompanying Comment</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_87_9_887_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_WNL.0000000000002970_WNL.0000000000002973.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002970">Neurology.org</ext-link></p></fn></fn-group><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">Dr. Kantarci: design or conceptualization of the study, data collection, analysis and interpretation of the data, drafting the manuscript, study funding. Ms. Tosakulwong: analysis or interpretation of the data, revising the manuscript. Mr. Lesnick: analysis or interpretation of the data, revising the manuscript. Ms. Zuk: analysis or interpretation of the data, revising the manuscript. Dr. Gunter: analysis or interpretation of the data, revising the manuscript. Dr. Gleason: data collection, analysis or interpretation of the data, revising the manuscript. Dr. Wharton: data collection, analysis or interpretation of the data, revising the manuscript. Dr. Dowling: analysis or interpretation of the data, revising the manuscript. Dr. Vemuri: analysis or interpretation of the data, revising the manuscript. Mr. Senjem: analysis or interpretation of the data, revising the manuscript. Dr. Shuster: analysis or interpretation of the data, revising the manuscript. Dr. Bailey: analysis or interpretation of the data, revising the manuscript. Dr. Rocca: analysis or interpretation of the data, revising the manuscript. Dr. Jack: analysis or interpretation of the data, revising the manuscript. Dr. Asthana: data collection, analysis or interpretation of the data, revising the manuscript. Dr. Miller: design or conceptualization of the study, data collection, analysis or interpretation of the data, revising the manuscript, study funding.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">This study is funded by the Aurora Foundation to the Kronos Longevity Research Institute and the NIH (NS66147, AG029624, and AG44170). The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">K. Kantarci serves on the data safety monitoring board for Pfizer Inc., Takeda Global Research &#x00026; Development Center, Inc. She is funded by the NIH (R01AG040042, principal investigator [PI], R21 NS066147 [PI], Mayo Clinic Alzheimer's Disease Research Center/project 1 P50 AG16574/P1 [PI], P50 AG44170/project 2 [PI], and R01 AG11378 [coinvestigator]). N. Tosakulwong, T. Lesnick, S. Zuk, J. Gunter, C. Gleason, W. Wharton, and N. Dowling report no disclosures relevant to the manuscript. P. Vemuri is funded by the NIH. M. Senjem holds stock in Gilead Sciences, Inc., Inovio Pharmaceuticals, Medtronic, Oncothyreon, Inc., and PAREXEL International. L. Shuster is funded by the NIH (P50 AG44170/core B [PI]). K. Bailey is funded by the NIH (P50 AG44170/core B [coinvestigator]). W. Rocca reports no disclosures relevant to the manuscript. C. Jack provides consulting services for Eli Lilly. He is funded by the NIH (R01-AG011378, RO1-AG037551, U01-HL096917, U01-AG032438, U01-AG024904) and Alexander Family Alzheimer's Disease professorship of the Mayo Foundation. S. Asthana is funded by the NIH. V. Miller is funded by the NIA (P50 AG44170 [PI]). Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002970">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">CEE</term><def><p>conjugated equine estrogens</p></def></def-item><def-item><term id="G2">FLAIR</term><def><p>fluid-attenuated inversion recovery</p></def></def-item><def-item><term id="G3">KEEPS</term><def><p>Kronos Early Estrogen Prevention Study</p></def></def-item><def-item><term id="G4">WHIMS</term><def><p>Women's Health Initiative Memory Study</p></def></def-item><def-item><term id="G5">WMH</term><def><p>white matter hyperintensity</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shumaker</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Reboussin</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia</article-title>. <source>Control Clin Trials</source>
<year>1998</year>;<volume>19</volume>:<fpage>604</fpage>&#x02013;<lpage>621</lpage>.<pub-id pub-id-type="pmid">9875839</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Shumaker</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Leng</surname><given-names>I</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years</article-title>. <source>JAMA Intern Med</source>
<year>2013</year>;<volume>173</volume>:<fpage>1429</fpage>&#x02013;<lpage>1436</lpage>.<pub-id pub-id-type="pmid">23797469</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LeBlanc</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Janowsky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>HD</given-names></name></person-group>
<article-title>Hormone replacement therapy and cognition: systematic review and meta-analysis</article-title>. <source>JAMA</source>
<year>2001</year>;<volume>285</volume>:<fpage>1489</fpage>&#x02013;<lpage>1499</lpage>.<pub-id pub-id-type="pmid">11255426</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prentice</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Langer</surname><given-names>RD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause</article-title>. <source>Am J Epidemiol</source>
<year>2009</year>;<volume>170</volume>:<fpage>12</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">19468079</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwin</surname><given-names>BB</given-names></name></person-group>
<article-title>Estrogen and memory in women: how can we reconcile the findings?</article-title>
<source>Horm Behav</source>
<year>2005</year>;<volume>47</volume>:<fpage>371</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">15708768</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waring</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Rocca</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Tangalos</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Kokmen</surname><given-names>E</given-names></name></person-group>
<article-title>Postmenopausal estrogen replacement therapy and risk of AD: a population-based study</article-title>. <source>Neurology</source>
<year>1999</year>;<volume>52</volume>:<fpage>965</fpage>&#x02013;<lpage>970</lpage>.<pub-id pub-id-type="pmid">10102413</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitmer</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Quesenberry</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yaffe</surname><given-names>K</given-names></name></person-group>
<article-title>Timing of hormone therapy and dementia: the critical window theory revisited</article-title>. <source>Ann Neurol</source>
<year>2011</year>;<volume>69</volume>:<fpage>163</fpage>&#x02013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">21280086</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaffe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sawaya</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lieberburg</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Grady</surname><given-names>D</given-names></name></person-group>
<article-title>Estrogen therapy in postmenopausal women: effects on cognitive function and dementia</article-title>. <source>JAMA</source>
<year>1998</year>;<volume>279</volume>:<fpage>688</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">9496988</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zandi</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Carlson</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Plassman</surname><given-names>BL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study [see comment]</article-title>. <source>JAMA</source>
<year>2002</year>;<volume>288</volume>:<fpage>2123</fpage>&#x02013;<lpage>2129</lpage>.<pub-id pub-id-type="pmid">12413371</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rocca</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Grossardt</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Shuster</surname><given-names>LT</given-names></name></person-group>
<article-title>Oophorectomy, estrogen, and dementia: a 2014 update</article-title>. <source>Mol Cell Endocrinol</source>
<year>2014</year>;<volume>389</volume>:<fpage>7</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">24508665</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harman</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Brinton</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Cedars</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>KEEPS: the Kronos Early Estrogen Prevention Study</article-title>. <source>Climacteric</source>
<year>2005</year>;<volume>8</volume>:<fpage>3</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">15804727</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harman</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Naftolin</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial</article-title>. <source>Ann Intern Med</source>
<year>2014</year>;<volume>161</volume>:<fpage>249</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">25069991</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleason</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Dowling</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Wharton</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the KEEPS Cognitive and Affective Study</article-title>. <source>PLoS Med</source>
<year>2015</year>;<volume>12</volume>:<fpage>e1001833</fpage>.<pub-id pub-id-type="pmid">26035291</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Shiung</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Gunter</surname><given-names>JL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD</article-title>. <source>Neurology</source>
<year>2004</year>;<volume>62</volume>:<fpage>591</fpage>&#x02013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">14981176</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowling</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Gleason</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance</article-title>. <source>PLoS One</source>
<year>2013</year>;<volume>8</volume>:<fpage>e68741</fpage>.<pub-id pub-id-type="pmid">23874743</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleason</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Dowling</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Wharton</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS&#x02013;Cognitive and Affective Study</article-title>. <source>PLoS Med</source>
<year>2015</year>;<volume>12</volume>:<fpage>e1001833</fpage>; discussion e1001833.<pub-id pub-id-type="pmid">26035291</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunter</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Shiung</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Manduca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Methodological considerations for measuring rates of brain atrophy</article-title>. <source>J Magn Reson Imaging</source>
<year>2003</year>;<volume>18</volume>:<fpage>16</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">12815635</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Cousens</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Scahill</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Harvey</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Rossor</surname><given-names>MN</given-names></name></person-group>
<article-title>Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects [see comment]</article-title>. <source>Arch Neurol</source>
<year>2000</year>;<volume>57</volume>:<fpage>339</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">10714659</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jayachandran</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tosakulwong</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>80</volume>:<fpage>911</fpage>&#x02013;<lpage>918</lpage>.<pub-id pub-id-type="pmid">23408873</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Resnick</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Jaramillo</surname><given-names>SA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study</article-title>. <source>Neurology</source>
<year>2009</year>;<volume>72</volume>:<fpage>135</fpage>&#x02013;<lpage>142</lpage>.<pub-id pub-id-type="pmid">19139364</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>MacFall</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Provenzale</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Steffens</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Krishnan</surname><given-names>RR</given-names></name></person-group>
<article-title>Differences in brain volumes among males and female hormone-therapy users and nonusers</article-title>. <source>Psychiatry Res</source>
<year>2006</year>;<volume>147</volume>:<fpage>127</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">16935478</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luoto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Manolio</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Meilahn</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Estrogen replacement therapy and MRI-demonstrated cerebral infarcts, white matter changes, and brain atrophy in older women: the Cardiovascular Health Study</article-title>. <source>J Am Geriatr Soc</source>
<year>2000</year>;<volume>48</volume>:<fpage>467</fpage>&#x02013;<lpage>472</lpage>.<pub-id pub-id-type="pmid">10811537</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boccardi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ghidoni</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Govoni</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of hormone therapy on brain morphology of healthy postmenopausal women: a voxel-based morphometry study</article-title>. <source>Menopause</source>
<year>2006</year>;<volume>13</volume>:<fpage>584</fpage>&#x02013;<lpage>591</lpage>.<pub-id pub-id-type="pmid">16837880</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberling</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Haan</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Mungas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Buonocore</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jagust</surname><given-names>WJ</given-names></name></person-group>
<article-title>Preliminary evidence that estrogen protects against age-related hippocampal atrophy</article-title>. <source>Neurobiol Aging</source>
<year>2003</year>;<volume>24</volume>:<fpage>725</fpage>&#x02013;<lpage>732</lpage>.<pub-id pub-id-type="pmid">12885580</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Janowsky</surname><given-names>JS</given-names></name></person-group>
<article-title>Preliminary evidence that long-term estrogen use reduces white matter loss in aging</article-title>. <source>Neurobiol Aging</source>
<year>2007</year>;<volume>28</volume>:<fpage>1936</fpage>&#x02013;<lpage>1940</lpage>.<pub-id pub-id-type="pmid">17030475</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lord</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Buss</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lupien</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Pruessner</surname><given-names>JC</given-names></name></person-group>
<article-title>Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect</article-title>. <source>Neurobiol Aging</source>
<year>2008</year>;<volume>29</volume>:<fpage>95</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">17030472</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sowell</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Welcome</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Henkenius</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Toga</surname><given-names>AW</given-names></name></person-group>
<article-title>Mapping cortical change across the human life span</article-title>. <source>Nat Neurosci</source>
<year>2003</year>;<volume>6</volume>:<fpage>309</fpage>&#x02013;<lpage>315</lpage>.<pub-id pub-id-type="pmid">12548289</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaye</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Swihart</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Howieson</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia</article-title>. <source>Neurology</source>
<year>1997</year>;<volume>48</volume>:<fpage>1297</fpage>&#x02013;<lpage>1304</lpage>.<pub-id pub-id-type="pmid">9153461</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Gilman</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease</article-title>. <source>Neurology</source>
<year>2005</year>;<volume>64</volume>:<fpage>1563</fpage>&#x02013;<lpage>1572</lpage>.<pub-id pub-id-type="pmid">15883317</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Condon</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lawrence</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Is cranial CSF volume under hormonal influence? An MR study</article-title>. <source>J Comput Assist Tomogr</source>
<year>1988</year>;<volume>12</volume>:<fpage>36</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">3335669</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Protopopescu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Hippocampal structural changes across the menstrual cycle</article-title>. <source>Hippocampus</source>
<year>2008</year>;<volume>18</volume>:<fpage>985</fpage>&#x02013;<lpage>988</lpage>.<pub-id pub-id-type="pmid">18767068</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pletzer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kronbichler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aichhorn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bergmann</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ladurner</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kerschbaum</surname><given-names>HH</given-names></name></person-group>
<article-title>Menstrual cycle and hormonal contraceptive use modulate human brain structure</article-title>. <source>Brain Res</source>
<year>2010</year>;<volume>1348</volume>:<fpage>55</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">20550945</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>VG</given-names></name>, <name name-style="western"><surname>Halliday</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Kril</surname><given-names>JJ</given-names></name></person-group>
<article-title>Neuropathologic correlates of white matter hyperintensities</article-title>. <source>Neurology</source>
<year>2008</year>;<volume>71</volume>:<fpage>804</fpage>&#x02013;<lpage>811</lpage>.<pub-id pub-id-type="pmid">18685136</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kloppenborg</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Nederkoorn</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Grool</surname><given-names>AM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cerebral small-vessel disease and progression of brain atrophy: the SMART-MR Study</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>79</volume>:<fpage>2029</fpage>&#x02013;<lpage>2036</lpage>.<pub-id pub-id-type="pmid">23115210</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayachandran</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Litwiller</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Owen</surname><given-names>WG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<year>2008</year>;<volume>295</volume>:<fpage>H931</fpage>&#x02013;<lpage>H938</lpage>.<pub-id pub-id-type="pmid">18621859</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>QG</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>RM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2011</year>;<volume>108</volume>:<fpage>E617</fpage>&#x02013;<lpage>E624</lpage>.<pub-id pub-id-type="pmid">21808025</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Tindle</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Bushnell</surname><given-names>CA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Brain volumes, cognitive impairment, and conjugated equine estrogens</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<year>2009</year>;<volume>64</volume>:<fpage>1243</fpage>&#x02013;<lpage>1250</lpage>.<pub-id pub-id-type="pmid">19729392</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaCroix</surname><given-names>AZ</given-names></name>, <name name-style="western"><surname>Chlebowski</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2011</year>;<volume>305</volume>:<fpage>1305</fpage>&#x02013;<lpage>1314</lpage>.<pub-id pub-id-type="pmid">21467283</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coker</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Hogan</surname><given-names>PE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies</article-title>. <source>Neurology</source>
<year>2014</year>;<volume>82</volume>:<fpage>427</fpage>&#x02013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">24384646</pub-id></mixed-citation></ref></ref-list></back></article>